Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.
Alderaan Biotechnology has raised €19M across 1 funding round from 1 investor, most recently a Series A round in Jan 2020. Based in Paris, France; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-01-09 | Series A |
| €19M |
| Advent France Biotechnology (AFB) and Medicxi |
| View deal → |
